Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Target Price of $5.46 According to Analysts

Cellectis S.A. (NASDAQ:CLLS) has received a consensus recommendation of “Hold” from the seven analysts that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $5.46.

CLLS has been the topic of several research reports. Robert W. Baird dropped their target price on Cellectis from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 15th. Barclays cut shares of Cellectis from an “overweight” rating to an “underweight” rating and reduced their target price for the company from $9.00 to $1.30 in a report on Wednesday, September 16th. Citizens Jmp reissued a “market perform” rating on shares of Cellectis in a research report on Tuesday, September 15th. Weiss Ratings raised Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. Finally, Wells Fargo & Company cut their price target on Cellectis from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Tuesday, September 15th.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Cellectis stock. Lido Advisors LLC purchased a new position in shares of Cellectis S.A. (NASDAQ:CLLS) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Stock Performance

Cellectis stock opened at $0.98 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61. The firm has a 50-day moving average of $2.10 and a 200-day moving average of $2.89. The firm has a market cap of $98.33 million, a P/E ratio of -1.51 and a beta of 3.00. Cellectis has a 1-year low of $0.88 and a 1-year high of $5.45.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04. The business had revenue of $6.90 million during the quarter, compared to the consensus estimate of $11.05 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

About Cellectis

Cellectis SA is a biotechnology company focused on developing gene-edited cell therapies for the treatment of cancer and other serious diseases. Founded in France in 1999, the company pioneered the use of TALEN gene-editing technology to modify immune cells and develop off-the-shelf, or allogeneic, treatments.

The company’s primary programs involve genetically modified T cells, including its UCART platform of allogeneic chimeric antigen receptor T-cell therapies. These products are designed to target specific cancer antigens and are being investigated in clinical studies for hematologic malignancies and other cancers.